Inside the research

Pfizer Inc.

PFE Research profile · latest available data

Price overview

$28.67

▲ +0.26 (+0.9%)

52w hi$29.02
52w lo$22.05
Vol27.76M
As of25 Sep 2026

The Verdict

Hold

Our score +0.31

Short+0.26
Medium+0.42
Long+0.22

computed 2026-09-27

Key fundamentals

Pfizer Inc.

Healthcare · Drug Manufacturers - General

Market cap$163.41B
Enterprise value$215.49B
Trailing P/E37.72x
Forward P/E9.90x
EV / EBITDA8.49x
P / S (ttm)2.57x
Profit margin6.8%
Return on equity5.0%
Revenue growth+2.6%
Debt / equity74.25

Layer Breakdown

LayerRawContribution
Fundamental+0.19
Sector+0.08
Technical+0.21
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

United States · www.pfizer.com

Risk Metrics

Beta vs SPX0.40
Corr SPX0.27
Annual vol24.3%
Annual ret+1.7%
Sharpe0.07
Max DD-28.5%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$29.11
High / Low$36.00 / $24.00
Median$28.00
Analysts27
Strong Buy2
Buy9
Hold15
Sell1
Strong Sell2

Recent rating actions

2026-04-29Citigroup→ Neutral
2026-04-20RBC Capital→ Underperform
2026-04-16CICC→ Outperform
2026-04-13UBS→ Neutral
2026-04-10Morgan Stanley→ Equal-Weight
2026-04-09B of A Securities→ Neutral

Officers & Board

DirectorJames Quincey since 2020
DirectorSusan Desmond-Hellmann since 2020
DirectorSusan Hockfield since 2020
DirectorScott Gottlieb since 2019
CEOAlbert Bourla since 2019
DirectorAlbert Bourla since 2018
DirectorDan Littman since 2018
DirectorRonald E. Blaylock since 2017
DirectorJoe Echevarria since 2015
DirectorJames C. Smith since 2014
DirectorShantanu Narayen since 2013
DirectorHelen Hobbs since 2011
DirectorSuzanne Nora Johnson since 2007
FounderCharles Pfizer current
FounderCharles F. Erhart current

Material Events

DateEvent8-K
2026-08-04Earnings Release, Exhibitsread
2026-06-18Officer / Director Change, Exhibitsread
2026-06-18Reg FD Disclosureread
2026-05-05Earnings Release, Exhibitsread
2026-04-27Shareholder Voteread
2026-02-03Earnings Release, Exhibitsread
2025-12-16Reg FD Disclosure, Exhibitsread
2025-11-21Other Material Event, Exhibitsread
2025-11-13Other Material Eventread
2025-11-04Earnings Release, Exhibitsread
2025-08-05Earnings Release, Exhibitsread
2025-05-19Other Material Event, Exhibitsread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share98.3%
HHI5,978 (concentrated)

Top Holders

HolderValueShares
State Street Corp$7.39B307.09M
Citadel Advisors$787.65M32.71M
Capital Research / Capital World$505.45M20.99M
AQR Capital Management$445.02M18.56M
Fidelity / FMR LLC$370.77M15.40M
Millennium Management$162.75M6.76M
Bridgewater Associates$4.34M180.09K
T. Rowe Price Group$349.57K14.52M

As of 2026-06-30

Dividends

Yield (TTM)4.50%
$ / share (TTM)$1.29
5y CAGR+3.6%

Annual dividend per share

2021$1.56
2022$1.60
2023$1.64
2024$1.68
2025$1.72
2026$0.86

SEC Filings

DateFormDoc
2026-08-1313F-HRview
2026-08-124view
2026-08-064view
2026-08-054view
2026-08-054view
2026-08-048-Kview
2026-08-0410-Qview
2026-08-034view
2026-07-164view
2026-07-134view
2026-07-014view
2026-06-304view
2026-06-304view
2026-06-304view
2026-06-304view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$62.58B+1.6%
Net income$2.12B-8.1%
Cash from ops$11.70B-2.2%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$28.45$28.69$28.17$28.6727.76M
Sep 24$28.20$28.85$28.20$28.4134.77M
Sep 23$27.96$28.23$27.84$28.1833.81M
Sep 22$27.74$28.00$27.49$27.9326.66M
Sep 21$27.65$27.92$27.53$27.7428.77M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →